importantSYS.SOURCE: National Design Studio• 2026-10-09T17:52:07Z

Rampart: On-Device PII Redaction for Browser-Based Privacy Protection

#privacy #ai #browser #open-source #pii

Rampart is an open-source browser-based system that uses deterministic rules and machine learning to remove personally identifiable information (PII) on-device before messages are sent. It prioritizes privacy by ensuring PII never leaves the user's device, combining regular expressions with a lightweight language model for context-aware redaction.

Read original article

*** END OF TRANSMISSION ***

> APPLE'S STRATEGIC MOVE: HIRING HUXE TEAM AND LICENSING AI TECHNOLOGY FOR PERSONALIZED PODCASTS > TAKESHI'S CASTLE: JAPANESE TELEVISION GAME SHOW AND INTERNATIONAL ADAPTATIONS > NVIDIA EXPLORES ACQUISITION OF US OPEN-SOURCE AI STARTUP REFLECTION AI > AI-DRIVEN WEB BROWSER PORTS OF CLASSIC GAMES DEMONSTRATE HIGH FUNCTIONALITY > DUCKDB 2.0 PERFORMANCE ENHANCEMENTS: ASYNC I/O AND RECURSIVE CTE OPTIMIZATIONS > PETRA POWER ADVANCES SOLID OXIDE FUEL CELL TECHNOLOGY FOR DATA CENTERS AND DEFENSE APPLICATIONS > CLOUDFLARE ACQUIRES DENO TO ENHANCE WORKERS PROGRAMMING MODEL > DONALD KNUTH'S ERROR REWARD CHECK FOR COMPUTER MODERN TYPEFACES > THE DOMINANCE OF PROTEIN IN BIOLOGICAL SYSTEMS > PHASE 1 CLINICAL TRIAL INITIATED FOR POPVAX'S BROADLY PROTECTIVE COVID-19 VACCINE PVX-001> APPLE'S STRATEGIC MOVE: HIRING HUXE TEAM AND LICENSING AI TECHNOLOGY FOR PERSONALIZED PODCASTS > TAKESHI'S CASTLE: JAPANESE TELEVISION GAME SHOW AND INTERNATIONAL ADAPTATIONS > NVIDIA EXPLORES ACQUISITION OF US OPEN-SOURCE AI STARTUP REFLECTION AI > AI-DRIVEN WEB BROWSER PORTS OF CLASSIC GAMES DEMONSTRATE HIGH FUNCTIONALITY > DUCKDB 2.0 PERFORMANCE ENHANCEMENTS: ASYNC I/O AND RECURSIVE CTE OPTIMIZATIONS > PETRA POWER ADVANCES SOLID OXIDE FUEL CELL TECHNOLOGY FOR DATA CENTERS AND DEFENSE APPLICATIONS > CLOUDFLARE ACQUIRES DENO TO ENHANCE WORKERS PROGRAMMING MODEL > DONALD KNUTH'S ERROR REWARD CHECK FOR COMPUTER MODERN TYPEFACES > THE DOMINANCE OF PROTEIN IN BIOLOGICAL SYSTEMS > PHASE 1 CLINICAL TRIAL INITIATED FOR POPVAX'S BROADLY PROTECTIVE COVID-19 VACCINE PVX-001